Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.

Saved in:
Bibliographic Details
Title: Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.
Authors: Tatovic D; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. tatovicd@cardiff.ac.uk., Marwaha A; University of Calgary, Calgary, Alberta, Canada. ashish.marwaha@ahs.ca., Taylor P; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK., Hanna SJ; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK., Carter K; Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University, Swansea, UK., Cheung WY; Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University, Swansea, UK., Luzio S; Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University, Swansea, UK., Dunseath G; Diabetes Research Unit Cymru, Institute for Life Sciences, Swansea University, Swansea, UK., Hutchings HA; Swansea Trials Unit, Swansea University Medical School, Swansea, UK., Holland G; Swansea Trials Unit, Swansea University Medical School, Swansea, UK., Hiles S; Swansea Trials Unit, Swansea University Medical School, Swansea, UK., Fegan G; Swansea Trials Unit, Swansea University Medical School, Swansea, UK., Williams E; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, Guy's Hospital, London, UK., Yang JHM; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, Guy's Hospital, London, UK., Domingo-Vila C; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, Guy's Hospital, London, UK., Pollock E; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, Guy's Hospital, London, UK., Wadud M; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, Guy's Hospital, London, UK., Ward-Hartstonge K; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada., Marques-Jones S; Patient and Public Representative, Ammanford, UK., Bowen-Morris J; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK., Stenson R; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK., Levings MK; BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.; Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada., Gregory JW; Division of Population Medicine, Cardiff University School of Medicine, Cardiff, UK., Tree TIM; Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, Guy's Hospital, London, UK., Dayan C; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Corporate Authors: USTEKID Study Group
Source: Nature medicine [Nat Med] 2024 Sep; Vol. 30 (9), pp. 2657-2666. Date of Electronic Publication: 2024 Jul 30.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-024-03115-2